Literature DB >> 19015160

Statistical monitoring of clinical trials with multivariate response and/or multiple arms: a flexible approach.

Lihui Zhao1, X Joan Hu, Stephen W Lagakos.   

Abstract

Randomized clinical trials with a multivariate response and/or multiple treatment arms are increasingly common, in part because of their efficiency and a greater concern about balancing risks with benefits. In some trials, the specific types and magnitudes of treatment group differences that would warrant early termination cannot easily be specified prior to the onset of the trial and/or could change as the trial progresses. This underscores the need for more flexible monitoring methods than traditional approaches. This paper extends the repeated confidence bands approach for interim monitoring to more general settings where there can be a multivariate response and/or multiple treatment arms and where the metrics for comparing treatment groups can change during the conduct of the trial. We illustrate the approach using the results of a recent AIDS clinical trial and examine its efficiency and robustness via simulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19015160      PMCID: PMC2648904          DOI: 10.1093/biostatistics/kxn037

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  12 in total

1.  Group sequential analyses for the mean function of a repeated measure process.

Authors:  X J Hu; S W Lagakos
Journal:  Stat Med       Date:  1999 Sep 15-30       Impact factor: 2.373

2.  Monitoring clinical trials with multiple arms.

Authors:  M Hellmich
Journal:  Biometrics       Date:  2001-09       Impact factor: 2.571

3.  Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.

Authors:  R M Gulick; X J Hu; S A Fiscus; C V Fletcher; R Haubrich; H Cheng; E Acosta; S W Lagakos; R Swanstrom; W Freimuth; S Snyder; C Mills; M Fischl; C Pettinelli; D Katzenstein
Journal:  J Infect Dis       Date:  2000-10-09       Impact factor: 5.226

4.  Design and analysis of group sequential clinical trials with multiple primary endpoints.

Authors:  Michael R Kosorok; Shi Yuanjun; David L DeMets
Journal:  Biometrics       Date:  2004-03       Impact factor: 2.571

5.  Sequential analysis of censored survival data from three treatment groups.

Authors:  R A Betensky
Journal:  Biometrics       Date:  1997-09       Impact factor: 2.571

6.  Sequential monitoring of clinical trials with multiple survival endpoints.

Authors:  P L Williams
Journal:  Stat Med       Date:  1996 Nov 15-30       Impact factor: 2.373

7.  Stopping guidelines for clinical trials with multiple treatments.

Authors:  M D Hughes
Journal:  Stat Med       Date:  1993-05-30       Impact factor: 2.373

8.  Interim monitoring of bivariate responses using repeated confidence intervals.

Authors:  R J Cook
Journal:  Control Clin Trials       Date:  1994-06

9.  Monitoring multi-armed trials.

Authors:  M A Proschan; D A Follmann; N L Geller
Journal:  Stat Med       Date:  1994 Jul 15-30       Impact factor: 2.373

10.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema.

Authors:  Alfred Fishman; Fernando Martinez; Keith Naunheim; Steven Piantadosi; Robert Wise; Andrew Ries; Gail Weinmann; Douglas E Wood
Journal:  N Engl J Med       Date:  2003-05-20       Impact factor: 91.245

View more
  2 in total

1.  Multiple event times in the presence of informative censoring: modeling and analysis by copulas.

Authors:  Dongdong Li; X Joan Hu; Mary L McBride; John J Spinelli
Journal:  Lifetime Data Anal       Date:  2019-11-15       Impact factor: 1.588

Review 2.  Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach.

Authors:  J M Kittelson; A C Spyropoulos; J L Halperin; C M Kessler; S Schulman; G Steg; A G G Turpie; N R Cutler; W R Hiatt; N A Goldenberg
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.